These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 33513407)

  • 21. Inadvertent dual therapy with dolutegravir and lamivudine in a pregnant patient living with HIV. A case report.
    Ferra-Murcia S; Gázquez-Aguilera EM; Díez-García LF; Collado-Romacho AR
    Enferm Infecc Microbiol Clin (Engl Ed); 2021; 39(6):305-306. PubMed ID: 34088455
    [No Abstract]   [Full Text] [Related]  

  • 22. Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine.
    Dumitrescu TP; Peddiraju K; Fu C; Bakshi K; Yu S; Zhang Z; Tenorio AR; Spancake C; Joshi S; Wolstenholme A; Adkison K
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):189-202. PubMed ID: 31724343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis.
    Allen Reeves A; Fuentes AV; Caballero J; Thomas JE; Mosley Ii JF; Harrington C
    Sex Transm Infect; 2021 Jun; 97(4):261-267. PubMed ID: 33782144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.
    Pereira GFM; Kim A; Jalil EM; Fernandes Fonseca F; Shepherd BE; Veloso VG; Rick F; Ribeiro R; Pimenta MC; Beber A; Corrêa RG; Lima R; Maruri F; McGowan CC; Schwartz Benzaken A; Grinsztejn B; Castilho JL;
    Lancet HIV; 2021 Jan; 8(1):e33-e41. PubMed ID: 33387477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
    Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A;
    J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of a Simplified Lamivudine Plus Dolutegravir Dual Therapy in HIV-1-Infected Patients: A Multicenter Cohort Study in China: Erratum.
    J Acquir Immune Defic Syndr; 2022 Dec; 91(5):516. PubMed ID: 36350800
    [No Abstract]   [Full Text] [Related]  

  • 27. Impact of nucleos(t)ide reverse transcriptase inhibitor resistance on dolutegravir and protease-inhibitor-based regimens in children and adolescents in Kenya.
    Kingwara L; Inzaule SC; Momanyi L; Jordan MR; Nyanya W; Bowen N; Oramisi V; Kiiru JN; Ngugi C
    AIDS; 2022 Mar; 36(4):611-613. PubMed ID: 34923516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.
    Boffito M; Waters L; Cahn P; Paredes R; Koteff J; Van Wyk J; Vincent T; Demarest J; Adkison K; Quercia R
    AIDS Res Hum Retroviruses; 2020 Jan; 36(1):13-18. PubMed ID: 31507204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two Cases of Viral Re-suppression After M184V + R263K Selection on Dolutegravir/Lamivudine Without Treatment Modification.
    Ursenbach A; Ruch Y; Hoellinger B; Fuchs A; Caspar S; Jegou F; Rey D; Fafi-Kremer S; Mesplède T; Gantner P
    Clin Infect Dis; 2024 Jul; 79(1):198-201. PubMed ID: 38193816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy.
    Calza L; Colangeli V; Borderi M; Testi D; Granozzi B; Bon I; Re MC; Viale P
    J Antimicrob Chemother; 2020 Nov; 75(11):3327-3333. PubMed ID: 32728708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
    Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
    Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dolutegravir plus lamivudine for the treatment of HIV-1 infection.
    Ciccullo A; Baldin G; Borghetti A; Di Giambenedetto S
    Expert Rev Anti Infect Ther; 2020 Apr; 18(4):279-292. PubMed ID: 32067525
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed People Living with HIV-1 Aged Over 65 Years.
    Calza L; Colangeli V; Legnani G; Cretella S; Bon I; Viale P
    AIDS Res Hum Retroviruses; 2024 Feb; 40(2):73-79. PubMed ID: 37335031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV.
    Sangaré MN; Baril JG; de Pokomandy A; Laprise C; Deshaies C; Klein M; Thomas R; Tremblay C; Roger M; Pexos C; Greenwald Z; Machouf N; Durand M; Hardy I; Dakouo M; Laporte L; Trottier H
    Medicine (Baltimore); 2020 Nov; 99(47):e23335. PubMed ID: 33217873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy.
    Gianella S; Marconi VC; Berzins B; Benson CA; Sax P; Fichtenbaum CJ; Wilkin T; Vargas M; Deng Q; Oliveira MF; Moser C; Taiwo BO
    J Acquir Immune Defic Syndr; 2018 Dec; 79(5):e112-e114. PubMed ID: 30383591
    [No Abstract]   [Full Text] [Related]  

  • 36. Two drugs regimens for HIV.
    Waters L; Church H
    Curr Opin Infect Dis; 2020 Feb; 33(1):28-33. PubMed ID: 31834030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Valuable combination partner. Great benefit for therapy naive patients].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():82-4. PubMed ID: 15373061
    [No Abstract]   [Full Text] [Related]  

  • 38. Less is more: A novel single-tablet regimen with two-drugs, dolutegravir/lamivudine.
    Sun J; Lu H
    Drug Discov Ther; 2021 Sep; 15(4):225-226. PubMed ID: 34334555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short Communication: Efficacy and Safety of Dolutegravir Plus Lamivudine as a First-Line Regimen in Clinical Practice.
    Ciccullo A; Baldin G; Dusina A; Cossu MV; Lombardi F; Borghetti A; Capetti A; Di Giambenedetto S
    AIDS Res Hum Retroviruses; 2021 Jun; 37(6):486-488. PubMed ID: 33587008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study.
    Lombardi F; Belmonti S; Borghetti A; Fabbiani M; Marchetti S; Tamburrini E; Cauda R; di Giambenedetto S
    J Antimicrob Chemother; 2020 Jun; 75(6):1599-1603. PubMed ID: 32101614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.